Financials Neutral

2026-05-29 22:01

CRITICAL RED FLAG DETECTED

Consolidated Revenue ₹37,706 million vs ₹32,562 million (▲15.8% YoY), with Q4 FY26 EBITDA at ₹7,626 million (20.2% margin) and PAT at ₹3,013 million (7.6% margin). The company also announced a landmark licensing deal with AbbVie for ISB 2001 worth up to USD 1.925 billion and received U.S. FDA EIR with VAI classification for its Monroe facility. Glenmark USA has agreed to settle antitrust litigation for USD 29.628 million.

Business Update Positive

2026-05-29 20:54

Glenmark Pharmaceuticals' Board approved the transfer of its Nebulizer brands/IP portfolio to Glenmark Healthcare Limited (GHL), a wholly-owned subsidiary, for a cash consideration of ₹223 Cr. The transfer, expected by June 30, 2026, aims to enhance strategic focus, operational agility, and long-term value creation for the robustly growing Nebulizer business segment, including establishing a new dedicated manufacturing facility within GHL.

Governance Negative

2026-05-29 20:46

CRITICAL RED FLAG DETECTED

Glenmark Pharmaceuticals Limited's Board Meeting on May 29, 2026, approved the early retirement of Mr. Harish Kuber as Company Secretary & Compliance Officer (KMP) effective May 29, 2026. Concurrently, Ms. Rashmi Khandelwal was appointed as the new Company Secretary & Compliance Officer (KMP), effective May 30, 2026. Additionally, Mr. Samir Kazi was appointed as Senior Management Personnel (Executive Vice President & Head Legal, Compliance & IP).

Financials Neutral

2026-05-29 20:21

CRITICAL RED FLAG DETECTED

Glenmark Pharmaceuticals reported consolidated revenue of ₹3,771 Cr for Q4 FY26 against ₹3,256 Cr in Q4 FY25, marking a 15.79% YoY increase. EBITDA rose by 35.92% YoY to ₹763 Cr from ₹561 Cr, with EBITDA Margin expanding by 299bps to 20.22% from 17.23%. Net Profit (PAT) increased significantly by 6772% YoY to ₹301 Cr from ₹4 Cr (due to a low base). The Board recommended a final dividend of Rs. 2.50 per share.

Financials Positive

2026-05-29 20:19

CRITICAL RED FLAG DETECTED

Consolidated Revenue ₹3,770.59Cr vs ₹3,256.21Cr (▲15.79% YoY), EBITDA ₹389.20Cr vs ₹188.21Cr (▲106.89% YoY), PAT ₹301.41Cr vs ₹4.65Cr (▲6381.9% YoY). EBITDA Margin 10.32% vs 5.78% (▲454bps). The company also recommended a final dividend of Rs. 2.5 per share.

Business Update Neutral

2026-05-29 14:36

Glenmark Pharmaceuticals Limited will host its Annual Investor Day 2026 on Tuesday, June 09, 2026, in Mumbai. The meeting, which will be held in physical and virtual mode, is for institutional investors and analysts to discuss the company's financial and operational performance based on investor presentations and updates.

Business Update Neutral

2026-05-23 15:04

Glenmark Pharmaceuticals Ltd. announced an Earnings Call to discuss its Q4 FY 2026 results. The call is scheduled for Monday, June 01, 2026, from 8:30 a.m. to 9:30 a.m. (IST). Dial-in details are provided for participants, and the recording will be available on the company's website within 24 hours.

Routine Neutral

2026-05-23 09:26

New Filing detected. See link for details.

Business Update Positive

2026-05-20 16:25

Ichnos Glenmark Innovation (IGI) announced a new development candidate, ISB 2301, a first-in-class multispecific immune cells activator targeting solid tumors. IGI intends to submit an IND application for ISB 2301 this year and begin clinical studies in 2027.

Governance Neutral

2026-05-19 16:53

Glenmark Pharmaceuticals Limited announced that a Board Meeting will be held on May 29, 2026, to consider and approve the Standalone and Consolidated Audited Financial Results for the quarter and year ended March 31, 2026. The Board will also consider and recommend a dividend for the year ended March 31, 2026. The trading window for designated persons will remain closed from March 31, 2026, to May 31, 2026.

Business Update Positive

2026-05-18 08:57

Glenmark Pharmaceuticals Inc., USA launched Vancomycin Hydrochloride for Injection USP (500 mg/vial and 1 g/vial) in the USA. The market for this product achieved annual sales of approximately $37.9 million for the 12-month period ending March 2026, strengthening Glenmark's injectable portfolio and commitment to affordable medicines.

Business Update Positive

2026-04-09 08:51

Glenmark Pharmaceuticals received U.S. FDA final approval for Progesterone Vaginal Inserts, 100 mg, which is bioequivalent to Endometrin® Vaginal Inserts. The product will be distributed in the U.S., adding to their women's healthcare portfolio. The market for this product had annual sales of approximately $59.2 million.

Ownership Neutral

2026-04-07 15:15

Glenmark Pharmaceuticals declares that no Promoter or Promoter Group encumbered shares, directly or indirectly, during the financial year ended 2025-26, as per Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

Business Update Negative

2026-04-01 19:10

CRITICAL RED FLAG DETECTED

Glenmark Pharmaceuticals received an Adjudication Order from GST authorities demanding ₹160.54 Cr for alleged short payment of CGST/SGST, plus interest and an equivalent penalty, for FY2019-20 and FY2020-21. The company disputes the demand and will file an appeal, stating no material financial impact.

Business Update Positive

2026-04-01 17:32

Glenmark Pharmaceuticals announced a strategic shift to directly commercialize and distribute its innovative product RYALTRIS® Nasal Spray in the U.S., effective April 1, 2026. This move aims to significantly expand its portfolio and build a stronger, direct U.S. commercial presence.

Business Update Positive

2026-03-21 00:29

Glenmark Pharmaceuticals launched GLIPIQ® (Semaglutide) in India on March 21, 2026, for Type 2 Diabetes Mellitus management. It sets a new affordability benchmark for GLP-1 therapy, with weekly treatment starting at ₹325, expanding patient access to advanced diabetes treatment.

Business Update Positive

2026-03-21 00:16

Glenmark Pharmaceuticals launched GLIPIQ® (Semaglutide) in India on March 21, 2026, for Type 2 Diabetes Mellitus. This launch sets a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at ₹325, aiming to expand access to advanced diabetes treatment.

Business Update Positive

2026-03-19 08:38

Glenmark Pharmaceuticals Inc., USA launched an authorized generic to Milnacipran Hydrochloride Tablets (Savella®) in the US market. The original product recorded annual sales of approximately $102.9 million for the 12-month period ending January 2026.

Business Update Positive

2026-03-19 08:36

Glenmark Pharmaceuticals received final FDA approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) in the U.S. and will launch it via Glenmark Therapeutics Inc. USA in April 2026. The reference drug market recorded annual sales of approximately $384.7 million.

Business Update Positive

2026-03-16 08:45

Glenmark Pharmaceuticals Inc., USA announced the launch of Potassium Phosphates Injection USP, a bioequivalent and therapeutically equivalent drug to Fresenius Kabi's reference listed drug. Distribution will begin in March 2026. The product's market had approximate annual sales of $50.7 million for the 12 months ending January 2026.

Business Update Positive

2026-03-04 08:38

Glenmark Specialty SA received U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg, with 180-day Competitive Generic Therapy Exclusivity. The product, targeting a $520.1M market, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc. starting March 2026.

Business Update Positive

2026-02-27 09:20

Glenmark Pharmaceuticals Inc., USA announced the upcoming launch of Sodium Phosphates Injection USP (15 mM P/5 mL, 45 mM P/15 mL, 150 mM P/50 mL) in April 2026. This product is bioequivalent to the reference listed drug and enters a market with annual sales of approximately $66.8 million.

Business Update Neutral

2026-02-20 17:30

Glenmark Pharmaceuticals disclosed on February 20, 2026, that NSE Sustainability independently assigned an ESG rating of '68' for F.Y. 2025, as per SEBI Regulation 30.

Business Update Neutral

2026-02-02 16:41

Glenmark Pharmaceuticals announced a schedule of analyst/institutional investor meetings on Feb 9, 11, 25, and Mar 9, 2026. The company stated no Unpublished Price Sensitive Information (UPSI) would be disclosed.

Business Update Neutral

2026-02-02 13:45

Glenmark Pharmaceuticals Limited announced the upload of the audio recording for its Q3 FY 2025-26 Earnings Call, held on February 02, 2026, on the company's website.

Business Update Negative

2026-01-31 21:16

CRITICAL RED FLAG DETECTED

Glenmark Pharmaceuticals reported a search and seizure/investigation by the Goods & Service Tax Department at its Mumbai offices from January 27 to January 31, 2026. The company stated it fully cooperated, found no adverse findings yet, and anticipates no material financial or operational impact.

Financials Positive

2026-01-30 20:59

Consolidated Revenue for Q3 FY26 was ₹39,006 Mn vs ₹33,876 Mn (▲15.1% YoY). EBITDA for Q3 FY26 stood at ₹8,697 Mn (22.3% margin) and PAT was ₹4,032 Mn (10.3% margin), which includes an exceptional item of ₹1,843 Mn.

Financials Positive

2026-01-30 20:53

Consolidated Revenue ₹3,900.6Cr vs ₹3,387.6Cr (▲15.1% YoY), EBITDA ₹869.7Cr vs ₹600.2Cr (▲44.9% YoY), PAT ₹403.2Cr vs ₹347.9Cr (▲15.9% YoY). EBITDA Margin 22.3% vs 17.7% (▲460bps).

Financials Positive

2026-01-30 20:50

CRITICAL RED FLAG DETECTED

Consolidated Revenue ₹3,900.62Cr vs ₹3,387.55Cr (▲15.14% YoY), EBITDA ₹914.21Cr vs ₹631.36Cr (▲44.80% YoY), PAT ₹403.23Cr vs ₹348.03Cr (▲15.86% YoY). EBITDA Margin 23.44% vs 18.64% (▲480bps).

GLENMARK

Glenmark Pharmaceuticals Limited

Filing History

Unlock Full History